Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 193

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 193
---
 loss through lifestyle changes alone. Historically, pharmacotherapy for obesity has had limited efficacy and significant safety concerns. However, the landscape has shifted dramatically with introducing GLP-1 receptor agonists and other hormone-targeting drugs that regulate appetite and satiety with improved safety profiles.

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 12 of 25 |

Several medications have been approved for weight management:

| ● | Semaglutide                                                        
 (Ozempic, Wegovy): A GLP-1 receptor agonist that promotes satiety. |

| ● | Tirzepatide                                                                                  
 (Zepbound, Mounjaro): A dual GIP and GLP-1 receptor agonist. Clinical trials have shown that 
 participants taking the highest dose of Zepbound lost an average of 48 lbs over 72 weeks.    |

| ● | Liraglutide                                                           
 (Saxenda): Another GLP-1 receptor agonist used for weight management. |

These medications are typically prescribed for individuals with a BMI ≥ 30 or ≥ 27 with weight-related comorbidities and are used alongside lifestyle interventions.

The most significant recent advancement in pharmacological treatment is glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the effects of the GLP-1 hormone, promoting insulin secretion, delaying gastric emptying, and inducing a feeling of fullness. Leading medications include:

| ● | Wegovy                                                                                    
 (semaglutide): The FDA approved Wegovy in 2021 for chronic weight management. In clinical 
 trials, it demonstrated an average weight loss of 15% of body weight. It is administered  
 via weekly subcutaneous injection.                                                        |

| ● | Ozempic                                                                                   
 (semaglutide): Originally developed for type 2 diabetes, Ozempic is widely used off-label 
 for weight loss and has surged in popularity globally.                                    |

| ● | Zepbound                                                                                  
 (tripeptide): Approved by the FDA in late 2023, Zepbound offers even greater efficacy. A  
 dual GIP and GLP-1 agonist, it showed a 22.5% average body weight reduction in late-stage 
 trials, surpassing all previous medications.                                              |

Liraglutide (Saxenda)

An earlier GLP-1 analog, Saxenda requires daily injections and yields average weight loss of